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 ". . . From the heart arise the vessels which go to the whole body . . . if the physician lay the 
hands or his fingers to the head, to the back of the head, to the hands, to the place of the 
stomach, to the arms or to the feet, then he examines the heart, because all his limbs possess 
its vessels, that is: the heart speaks out of the vessels of every limb . . . If the heart trembles, 
has little power and sinks, the disease is advancing.”   
The Papyrus Ebers, c. 1534 BC (Stern,1875). 
1. Introduction 
Cardiovascular disease (CVD) is the first cause of mortality in developed countries, 
responsible for one death every 34 seconds and the estimated global annual cost is $ 403.1 
billion according to recent statistics from the United States (Thom et al., 2006).   
Furthermore, congestive heart failure (CHF) has been defined by the NIH, as the new 
epidemic in the USA, affecting more than 5 million new cases per year with a 5-year 
survival rate of less than 50% (Zickmund, et al. 2006). 
Current therapies for CHF patients include medicinal provision of drugs such as cardiac 
glycosides, diuretics, AC inhibitors, anticoagulant (Couzens, 2009). However, medicinal 
therapies are usually insufficient necessitating complementary supports e.g., mechanically 
with cardiac assist devices (CAD) and/ or biologically with surgical procedures up till 
orthotopic heart transplants as an ultimate procedure. 
Meanwhile, orthotopic heart transplant is still restricted due to the shortage of donors, plus 
operative morbidity and mortality (Schmauss & Weis, 2008). 
Mechanical cardiac assist device (CAD) is usually used temporarily until the patient’s 
hemodynamics improve, may offer an intermediate solution for the lake of donors as a bridge 
to a heart transplant (Park, et al., 2003), but in the heavy price of several disadvantages. 
Permanent replacement of the heart with an artificial heart option is still a work in progress 
(Carpentier, 2011), with current technology having a short life expectancy. Thus, the artificial 
heart is primarily used as a bridge to transplant for patients wit biventricular failure. 
Furthermore the large size of an artificial heart limits its applications in specific categories, 
regarding body surface area (1.9±0.22 m2), sex (95% men) and age (practically 0% children) 
(Roussel, et al., 2009). 
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Unfortunately, those aforementioned therapies still represent cost-effectiveness dilemma for 
health care systems in modern societies due to high cost, morbidity and mortality.  
As a potential solution we are proposing a new therapeutic approach based on a 
fundamental revision of the entire circulatory system in correspondence to the 
physiopathology and physics laws applications with new generation of CAD. 
The aim is directed to support and restore organ function, rather than to be replaced. Thus, 
it seeks to remedy the drawbacks of the state of present therapies and includes the 
innovation of new devices for providing cardiopulmonary and circulatory assistance. 
This proposed therapy is based on a main concept (Think endothelial) and on a new 
hemodynamic theory entitled (Flow and Rate) that seeks to improve hemodynamics, organs 
microcirculations, restore and preserve the endothelial function by maintaining shear stress-
mediated endothelial function with circulatory dynamics forces e.g., pressurized flow and 
shear rate (Nour, 2006). 
1.1 Concept 
Conceptually, the cardiovascular system is a closed pressurized hydraulic circuit (Figure 1), 
which is lined internally with endothelial cells (Samet  & Lelkes, 1999; Furchgott, 1981). 
Endothelium is constantly exposed to blood components and pulse pressure known as the 
tangential forces of shear stress (Hoeks et al., 1995). 
 
Fig. 1. Circulatory system's shear stress-mediated endothelial function 
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Shear stress controls and maintains endothelial function, which comprises the vascular tone 
by the synthesis of nitric oxide (NOS), blood coagulation, the inflammatory response, 
atherosclerosis, angiogenesis and apoptosis (Petrovic, et al., 2000; Limaye & Vadas, 2007; 
Lam et al., 2006). 
In other terms, shear stress-mediated endothelial function controls embryogenesis, 
morphogenesis, organogenesis and maintenance of a healthy organism (Adamo, 2009). 
In general, fluid movement in hydraulic circuits, which means momentum transfers with 
frictional losses, depends on driving forces, resistances, viscosity and conduits geometries 
(Kessler & Greenkorn, 1999). 
The heart and peristaltic arteries represent the main circulatory driving forces that usually 
affect the left heart side. 
Otherwise, accessory forces such as the respiratory pump, muscle pump, gravity, 
atmospheric pressure, oncotic pressure, skin baroreceptors, venous valves, pericardium, etc., 
are necessary to move up the steady blood flow at the right heart side (Nour, et al., 2009). 
Endothelium controls vasoconstriction (e.g. catecholamine), vasodilatation with mediators 
like nitric oxide (NO) and vascular conditions with several processes like atherosclerosis 
and angiogenesis-apoptosis interdependency. This simply means that vascular resistances 
depend on vascular tone and vessels elasticity that are controlled mainly by shear stress-
mediated endothelial function. 
2. Fluid mechanics and cardiovascular pathophysiology 
The clinical application of endothelial shear stress (ESS) should be realized in 
correspondence to cardiovascular biophysics, pathophysiological conditions as well as laws 
of fluid mechanics. This means a CAD should adapt the different criteria of each circuit of 
the right and left heart side (Figure 2), as follows:   
1. The left heart circuit: it is characterized anatomically, by two high remodeling zones 
that represent the main circulatory pumps: the left ventricle (LV) and the aorta with the 
Valsalva as been shown on (Table1) and (Figure 2). Flow dynamics inside the Valsalva 
sinuses determines coronary ostia morphogenesis (Hutchins, 1988) and may contribute 
to a severe hemodynamic deterioration (Palmieri, 2001). So a shear stress-mediated 
endothelial function must be induced at the left heart side according to the Newton’s 
principles by maintaining a physiological arterial pulse pressure (Feynman, et al., 2005). 
The LV almost, triples its myocardial mass during the first postnatal month with an 
important arterial angiogenesis. (Kozák-Bárány, 2001). According to Laplace’s law, 
this LV remodeling could be enhanced by the posterior location of the LV (behind the 
RV), less limited by the pericardium and sternum, which increases the gravity effect, 
particularly in the neonatal supine position. The LV remodeling will be continued 
and maintained later on, influenced by ESS, the spherical shape of the LV (Yacoub, 
1995), the elevated vascular resistances and the gravity effect at the aortic 
root. Disturbed flow dynamics at the left heart side induce atherosclerotic lesion 
(Samady, et al. 2011)), which is uncommon at the right heart side pulmonary arterial 
walls, most probably due to the constant delivery of ESS by the respiratory pump. 
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Fig. 2. Left and right heart circuits different remodeling zones 
 
Zones Sites Remodeling Main Factors 
Z1 LV High 
  Laplace  posterior to RV less restricted by the 
pericardium;  Newton  spherical shape 
(Tumkosit M 2007);  resistances. 
Z2 
Aorta + 
Valsalva 
High 
 Shear stress (Newton): peristaltic pump + 
gravity effect at the Valsalva;  Laplace (less 
restricted external sheath at the arch),  
resistances. 
Table 1. Left heart postnatal remodeling zones LV= left ventricle. 
2. The right heart circuit: contrarily to the left, the right heart could adjust blood volume 
and shear rates at 5 different anatomical zones according to its physiological demands. 
In antenatal period, the right heart receives and pumps in equal rates more volume than 
the left, but keeps low remodeling due to pressure release through physiological shunts 
(Clark, 1987). After birth and shunts closure, both right and left ventricles share equal 
volume and rate inducing equal pulmonary and systemic cardiac output (CO), but 
remodeling remains inferior at the right heart side most probably due to venous steady 
flow and ventricular wall trabeculae. As shown in (Table 2) and (Figure 2), it could be 
identified by five different remodeling zones (Nour, 2009). Normally, the respiratory 
pump increases shear rates at the pulmonary endothelium externally creating an 
indirect or reversed pulse pressure shear stress (Newton). But with zones of steady flow 
and others with low pulse pressure the situation becomes more complex with physics 
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laws applications. In fact, both Bernoulli (Calvert, 2000), and Newton in addition to the 
gravity effect of Pascal’s law as well (Humbert, 1947), must be considered to deliver a 
shear stress-mediated endothelial function. 
Most importantly, the delivery of ESS with a CAD should be induced without 
disturbing the physiological remodeling of the right heart circuit (Buckberg, 2006). 
Direct induction of shear stress according to Newton’s law like with an intravenous or 
intrapulmonary pulsatile perfusion must be avoided as it could induce serious 
hemodynamic conditions such as an irreversible pulmonary remodeling such us the 
Eisenmenger syndrome (D'Alto M, et al., 2007) or coronary bypass venous grafts 
disease. Also, the RV is preload dependant, that could not tolerate to be unloaded 
(Nour, 2009).  This may explain failure of current pulsatile CAD in case of RV failure. 
 
Zones Anatomical site Remodeling Main Factors
Z1 SVC, IVC Low Absence of shear rates  Steady flow
Z2 A-V cavity Mild Trabeculae
Z3 Septum Normal Receiving interseptal left & right coronary supply 
Z4 Infundibulum High  Coronary flow
Z5 PA tributary Low Pressure, Pulmonary Valve + Infudibulum 
Table 2. Right heart postnatal remodeling zones (Nour et al 2009): SVC, IVC: superior & 
inferior vena cava respectively; A-V: atrioventricular;  PA: pulmonary artery. 
3. Hemorheological stock: the right heart circuit contains > 64% of blood volume 
surrounded by an important mass of endothelial cells. This natural stock of blood volume 
and endothelial mass can be stimulated by a proper pulsatile CAD, adaptable for right 
heart circuit’s biophysics and physiopathology, for inducing shear stress-mediated 
endothelial function enhancement. Contrarily, to current evidence of high mortality of 
CHF patients associated with right heart failure (Haddad, 2011), the concept of the present 
therapeutic approach considers the right heart as a physiological backup for management 
of almost all types of hemodynamic and circulatory disorders, including CHF patients 
(Nour S, 2009). As been demonstrated on (Table 3), the right heart afterlaod could 
improve or deteriorates the global cardiac output (CO) and hemodynamic, for example 
nitrates therapies that could improve left ventricular MI by lowering the systemic 
afterload, may worsen and be fatal in case of RV ischemia (Haji, 2000).  
 
Vascular Resistances Status Right heart Left heart
Systemic Low Bad hemodynamic1 Good hemodynamic 
Systemic Elevated Good hemodynamic2 Bad hemodynamic 
Pulmonary Low Good hemodynamic Good hemodynamic 
Pulmonary Elevated Bad hemodynamic Bad hemodynamic 
Table 3. Dominancy of the right heart over the left heart through pulmonary vascular 
resistances (Nour, 2008):1= i.e. nitrates therapy in right ventricular ischemia; 2= i.e. 
epinephrine therapy with cyanotic spells 
4. Pulmonary afterload: the influence of the right heart on hemodynamics is observed by 
the immediate postnatal drop of the pulmonary vascular resistances, triggered by the 
external shear stress-mediated endothelial function induced by the respiratory pump 
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(creating an indirect internal pulse pressure closer to Newton’s law). Another example 
is observed in patients in squatting position during cyanotic spells of Tetralogy of Fallot 
(TOF) that increases the systemic vascular resistances (Senzaki, 2008) and increases the 
intrapulmonary flow and shear rates in a retrograde manner through the malaigned 
VSD to lower the pulmonary vascular resistances, followed by global hemodynamic 
improvement. The increased intrapulmonary shear rate that can be induced by 
adrenaline injection as well during the cyanotic TOF spells (Table 3), provides shear 
stress-mediated endothelial function approaching Bernoulli’s law. Reduction of 
pulmonary vascular resistances is an immediate target for hemodynamic improvement 
that can be achieved by shear stress-mediated endothelial function enhancement 
directly with an intrapulmonary shear rate enhancement device (e.g. pulsatile catheter); 
or indirectly with an external pulsatile device (e.g. pulsatile suit). 
5. Microcirculation: as is known, human being is a multicellular organism in which 
cellular biology performs a main role in terms of development, maintenance, proper 
operation and also failure of vital organs (Vincent, 2008). Maintaining good operation of 
organs by means of microcirculation in the organ constitutes a characteristic effect of 
the proposed concept. Microcirculations are controlled by plurality of endothelial 
mediators of vasodilators, which are dependent on shear stress (Koller, 1993) 
(Poelmann, 2008). Under normal hemorheological condition, microcirculation behavior 
approaches that of Newton’s law. A symbolic example observed in athletics, high 
physical performance, which means shear stress-mediated endothelial function, could 
be achieved with slow heartbeat (shear rate) and increased stroke volume (pulse 
pressure). In contrast, in any abnormal hemorheological state, microcirculation presents 
behavior that approaches that of Bernoulli’s law, as interpreted by the Fahraeus-
Lindqvist effect in which plasma stuck at the inner vascular boundary layers while 
erythrocytes move faster at the center (Fahraeus & Lindqvist, 1931; Neri Serneri, 1981). 
This could explain absence of cyanosis in anemic patients with low hematocrite, unlike 
those patients with high hematocrite, as erythrocytes aggregations at microcirculations 
induce cyanosis with clinical signs finger clubbing (drumsticks fingers). 
2.1 Cardiovascular pathogenesis 
Endothelial dysfunction is responsible for almost all types of cardiovascular pathogenesis 
whatever congenital or acquired (Endemann et al., 2004) 
The dependency of the endothelium on shear stress stimuli starts by the placental 
angiogenesis since the 6th gestational day, once there are normal hemorheolgical maternal 
factors (Heilmann, et al, 2005). Troubled shear stress forces due to an increased blood 
pressure (e.g.,preeclampsia) or low hematocrit (anticoagulant drugs), induces congenital 
anomalies and could interrupt the course of pregnancy (Aron, et al., 2003). 
By the 8th gestational day of the intrauterine life, the embryonic vasculogenesis starts due to 
shear stress enhanced endothelial function, creating the first blood vessels followed by the 
appearance of the first fetal heartbeat by the 21st day (Meyers, 2007). 
Furthermore, disturbed flow dynamics in the prenatal period, could induce congenital 
anomalies (Al-Ghazali, et al., 1989). Some symbolic examples of cardiac malformations are 
resumed on (Table 5) of cardiac malformations on (Table 4). 
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Flow disturbances Congenital malformations 
No flow  no grow Hypoplastic left heart syndrome (Rao, 1994) 
Homogenous flow Heterotaxy syndrome (Prendiville, 2010). 
Excessive flow Agenesis pulmonary valves (Yeager, 2002). 
Modified flow Conotruncal defects: TGA, TOF, DORV, DOLV, (Rothenberg, 2003). 
Table 4. Congenital malformations with troubled flow dynamics: TGA = transposition of 
great arteries; TOF= tetralogy of Fallot; DORV, DOLV= double outlet right or left ventricle 
respectively. 
In the postnatal period, endothelial dysfunction is a major predisposing factor to 
hemodynamic troubles, circulatory disorders such as diabetes (Kapur A, De Palma R., 2007), 
arterial hypertension (Martini, et al., 2006), atherosclerosis (Chatzizisis, et al., 2007) and life-
threatening conditions (e.g. cardiogenic shock, multiple organ failure). This could be 
induced by disturbed flow dynamics due to pump failure and/or elevated vascular 
resistances. As a symbolic example, right ventricular (RV) failure can occur either due to 
elevated pulmonary vascular resistances caused by pulmonary oligemia, pulmonary 
hyperemia; or due to RV pump failure caused by ischemia, congenital anomalies, 
arrhythmia, valvulopathy, and/or accessory circulatory driving forces failure like with 
failed Fontan’s operation (Pereira & Shirali, 2005). 
2.2 Types of endothelial dysfunction 
Practically, and in a matter to facilitate the therapeutic approach for cardiovascular 
pathologies, endothelial dysfunctions could be classified into three categories as follows 
(Nour, 2009): 
 Type A: endothelial dysfunction manifested with heart failure. 
 Type B: includes endothelial dysfunction patients with endothelial dysfunction with 
normal heart function (e.g. diabetic, systemic arterial hypertension, PAH, erectile 
dysfunction, etc). 
 Type C: represented by healthy individuals, liable for endothelial dysfunction 
pathogenesis under certain circumstances like disturbed atmospheric pressure and 
gravity (e.g. Astronauts, professional scuba divers, bedridden); fatigue, increased 
inflammatory responses, increased apopotosis (e.g. athletics, early aging processes). 
2.3 Endothelial dysfunction vs. current CVD therapies 
Usually, endothelial dysfunction occurs as a consequence of pathological and/or 
interventional cardiovascular conditions, unfortunately with bad prognosis as there is no real 
curative option. A symbolic example, as been schematized in (Figure 3), regarding the current 
management of ischemic heart disease (IHD), which is still the leading cause of death so far. 
Except cracking or bypassing atheroma nothing has been done effectively until present. 
As been resumed in (Figure 3): there are three symbolic “R” therapeutic options of 
myocardial ischemia which means: Reperfusion through an interventional and/or surgical 
approach; Rehabilitation, with physical exercise or CAD; Replacement with cellular therapy 
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(WU KH, et al., 2006) or heart transplants. Also there are three conflictual therapeutic factors 
“F”: F1 due to patients clinical varieties like with unstable angina; silent ischemia; ST-
elevated myocardial infarction (STEMI) or non-ST elevated myocardial infarction (NSTEMI); 
mechanical complications of IHD; cardiogenic shock (Berger PB, et al., 1999); age or sex. This 
is complicated by anatomical variation; variations in myocardial damage that affects the 
septum, right or left ventricular regions (Haji SA & Movahed, 2000); and variable coronary 
pathology, including normal, spasmodic, vasculitis, (Newburger, et al., 2004), or classical 
coronary atherosclerosis. Second factor (F2) is related to therapeutic defects like with 
nitrates tolerance (Abrams J, 1988); finally the most important factor (F3) is the maintained 
endothelial dysfunction (e.g. atheroma).  
Unfortunately, all those therapeutic options could not resolve the problem, means to restore 
the main cause of dysfunctional endothelial atherosclerotic plaques (Davignon , et al., 2004). 
In addition, there are several varieties of MI due to other endothelial dysfunction 
pathogenesis rather than atherosclerosis such as coronary spasm (Kusama, et al., 2011) or 
congenital anomalies (McCrindle, et al.  2007), that could not be managed easily with 
angioplasty or coronary grafts (Gershlick & Thomas, 2007). 
 
Otherwise, restorations of the endothelial function could be provided by the present concept (3R-in-one). 
Fig. 3. Current therapeutic options for Myocardial infarction (MI) 
3. Current CADs and endothelial dysfunction 
In case of disturbed hemodynamic with heart failure, additional circulatory driving forces 
might be needed such as: a) Bio-assists with surgical procedures like the aortomyoplasty 
(Bolotin, et al (2001), cardiomyoplasty (Chachques, et al.,2005), and heterotopic heart 
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transplants (Onuzo, et al., 2000); and/or b) mechanical assists devices: like the 
cardiopulmonary bypass (CPB), left ventricular assist device (LVAD) (Seyfarth, et al., 
2008)or right ventricular assist device (RVAD), and the artificial heart (Unger, et al.,1988). 
In general, the present arts of cardiac assists devices can be classified in two categories: 
1. Devices that increase coronary blood flow during diastole, in order to improve the 
oxygenation and thus the performance of the myocardium. This category includes the 
intra-aortic balloon pump (IABP), (Burkhoff , et al., 2006) and the enhanced external 
counterpulsation pump (EECP), (Bonetti, et al. 2003). These devices must be 
synchronized with heartbeat and unsuitable in case of cardiac arrhythmia; and 
2. Devices that unload and bypass the heart pump: either partially as achieved by left 
ventricular assist devices (LVAD), right ventricular assist devices (RVAD), and by 
extracorporeal membrane oxygenation (ECMO); or completely like with biventricular 
assist devices, extracorporeal circulation (CBP), hetertopic heart transplant. It should be 
emphasized that ECMO partially deviates some of the venous blood to an external 
membrane oxygenator. ECMO does not completely unload the right ventricle (RV) and 
that may explain its successful applications in pediatrics patients who are more 
frequently vulnerable to RV failure (Wilmot, et al. 2011). 
As a matter of fact, development of CAD remains controversial due to the induced 
momentum energy losses with the tasks of increased morbidity and mortality. 
Most probably, CAD may aggravate hemodynamics, leading to multiple organ failure and 
death due to several factors that could be directly linked to devices themselves or indirectly 
due to patients’ related factors as follows: 
1. Devices related factors: 
a. Concept and design: a CAD is typically a lumped model constructed according to laws 
of physics for driving a Newtonian compressible fluid inside a closed pressurized 
hydraulic circuits (Roselli RJ & Brophy, 2003), implementing rigid tubes with fixed 
diameter. Meanwhile in practices a CAD is confronted with a non-Newtonian fluid 
(blood, running in flexible vessels with different geometries). This confrontation 
between two opposite pressurized hydraulic circuits (Figure 4) creates a vicious circle 
of momentum energy losses manifested clinically by increased vascular resistances 
with endothelial dysfunction (e.g. hemorrhage, thromboembolism, inflammatory 
response, apoptosis, etc.), up till multiple organ failure. 
b. Driving forces’ drawbacks: more precisely, roller or centrifugal pumps are usually 
used to circulate and perfuse blood between the patient and the external circuit 
most commonly in a steady flow mode of perfusion (Gravlee, 2008). Unfortunately 
even with biocompatible, materials the effect of sucking and pumping a fragile 
fluid like blood mechanically with impellers, propellers, or pulsed reservoir, inside 
narrow rigid conduits create a zone of turbulence and vortices with important 
energy losses (Geankoplis, 2005). This improper simulation of a ventricular 
function with current CAD, as it is practically impossible to replace a type III 
passive pump like the heart, by type II, or I pump (Anderson,1999). 
c. Installations systems: usually conduits of tubes, and cannula, made of biocompatible 
materials (e.g. PVC®, Dacron®, PTFE®, etc.), are used for connection between 
patient and CAD. In addition, those conduits need to be securely stitched to 
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cardiovascular tissues, diverted under the skin (tunnelization) to allow proper 
chest closure, then to be de-aired and checked for leakage or gas emboli before 
finally connected to their corresponding CAD. Furthermore, the distance between a 
CAD and the patient’ inlet/outlet sites gives rise to dead space, creating an 
additional momentum energy losses zone(please refer to Figure 8). Finally, the 
procedures for installing such conduits need to be carried out by experienced 
surgeons in specialized centers on patients who are fragile, and who have usually 
already been operated on several times in the past, increasing the risks of 
morbidity and mortality (e.g. hemorrhages, vascular complications, infections, 
multiple organ failure). 
 
Fig. 4. Circulatory system and CAD create two opposite hydraulic circuits dilemma 
2. Patients related factors: The aggravating factors inherent to the patients themselves can 
be of several kinds such as: 
a. Age, sex: most CAD devices are unsuitable for patients with small body surface 
area (e.g. children, female) since more than 80% of CAD devices are designed for 
body areas of more than 1.5 m2, i.e. corresponding to adult heart patients. In 
addition CAD are generally first designed for management adult heart diseases 
and then miniaturized to cope with pediatric populations. However; pediatric 
patients are more vulnerable to hemodynamic disturbances caused by right heart 
failure due to congenital anomalies and they are vulnerable to vascular 
complications caused by small vessels geometries in content (Potapov, et al 2007). 
Adults usually suffer from ischemic left ventricular heart diseases with 
atherosclerotic vessels and they are therefore more vulnerable to vascular 
complications (Nour S, 2008). 
b. Etiology: fate of CHF patients with severe right ventricular (RV) failure 
(CVP>16mmHg) is worse, compared with those patients with left heart sided 
pathologies. Current therapies employing CAD to treat CHF patients with severe 
RV failure (Prutkin et al. 2008), still exhibit a high mortality rate (65%-95%), most 
probably due to insufficient understanding of the great difference between the 
right and left heart circuits (Sollano, 1998). 
c. Preclinical studies: in particular, the role of animal models in therapeutic 
evaluation, which is an extremely essential procedure before proceeding to clinical 
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applications of new CAD. However, there is still a gape between the chosen animal 
model and clinical realities as presented in the following examples: 
i. Current models of myocardial infarction are unfortunately, driven by costs 
rather than clinical resemblance. For example, rat as a most popular selected 
model is far from human physiopathology with a heart rate> 400 bpm.  
ii. Models of acute pulmonary hypertension (PAH), as often done either by 
hypoxia, monocrotaline, or systemic-pulmonary shunt. However, a lack of 
robust models of PAH, is still missing due to different spectra of lung tissue 
between species and humans (Robbins, 2004), (Bauer, et al. 2007). 
iii. The biventricular heart failure models, often called for testing of cardiac assist 
devices, which remain difficult to achieve in animals. The most part of 
these mechanical assists devices are usually tested in computational version 
(Querzoli, 2011) or WindKessel models, away from the pathophysiological 
aspect in humans (Olufsen & Nadim A, 2004). 
d. Miscellaneous: finally, the shortage of donors, immunosuppressive drugs 
drawbacks (e.g. malignancy); coronary atherosclerosis, follow up costs and surgical 
complications, all contribute to limiting the generalization of such treatments in 
practice. 
4. Proposal 
The present concept proposes clinical applications of these tangential forces of shear stress 
in order to regulate the endothelial function so as to improve the hemodynamic of patients, 
the overall microcirculation of vital organs, and, when it has failed, to reestablish normal 
operation of the cardiac pump in a manner that is as physiological as possible, without 
replacing any organs and without any traumatic intrusion, to provide a method that is as 
minimally invasive as possible. 
Development of a CAD* with an optimum function, which means improving hemodynamics, 
increasing organ microcirculation, restoring and preserving deficient endothelial function in a 
diseased human being, should compromise the following steps: maintaining the circulatory 
flow dynamics in the patient’s systemic and pulmonary circulations; and temporarily relieving 
the heart of its pumping function.  
* CAD is referred to a “circulatory assist device”, instead of the commonly applied term “cardiac 
assist device”. 
More precisely there are three manners to stimulate the endothelium with a mechanical 
assist device as follows (Figure 5): 
1. Direct internal endothelial stimulation that will be induced by an intravascular catheter 
device. 
2. Indirect internal endothelial stimulations with a pulsatile perfusion flow generated by a 
pulsatile pipe (tube) device at the left heart side. 
3. External stimulation (pulsatile suit) at the right heart side endothelial with gentle 
rhythmic squeezing of the venous and lymphatic capacitances reservoirs at the 
superficial veins and capillaries.    
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Fig. 5. Methods for shear stress-mediated endothelial function stimulations 
According to the present concept, the method consists in using at least one device external 
to the patient’s body and connected by at least a pipe and/or a specific connection element 
to: 
1. Increase the preload of the right ventricle so as to improve myocardial oxygenation and 
so as to improve its contractility; and/or 
2. Unload the left ventricle and diffuse regular pulsatile flow in the proximity of the aortic 
root so as to improve the hemodynamics of the left ventricle of the heart; and/or 
3. Stimulate the endothelium mechanically by shear stress enhancement so as to release 
several mediators of endothelial vasodilators like nitric oxide (NO), to reduce the 
systemic and pulmonary vascular resistances (afterload). 
5. Synchronization with the diastolic phase 
The synchronization of these new pulsatile CAD with the heartbeat is strictly guided by the 
therapeutic indications according to types of endothelial dysfunction as follows (Nour S, 
2009): 
 Type A: this means in case of heart failure, CAD’s synchronization is unnecessary and 
must be unsynchronized with heartbeat. 
 Type B: synchronization of CAD with the heart is necessary to restore the endothelial 
function. 
 Type C: synchronization of CAD is relative, because according to the Starling’s law 
(Katz, 2002), the cardiac output (CO) adapts to the venous return (RV preload). 
6. Devices 
In known manner, the prior art constituted in particular by circulatory assistance systems 
such as LVAD, RVAD, Biventricular AD, etc., simulate the ventricular pump by complex 
driving forces. 
In a manner that is very different, and indeed that is opposite in the physical sense of the 
word, the devices and methods of the present concept are designed to maintain circulation 
www.intechopen.com
 “Flow and Rate”: Concept and Clinical Applications of a New Hemodynamic Theory 29 
in columns of blood within their own physiological containers as constituted by veins and 
arteries. The idea is to maintain a pulsatile blood stream complying with the biophysical and 
physiological standards of pulmonary and systemic circulations, by applying mechanical 
endothelial stimuli of shear stress. 
One aspect of the devices and methods of the present concept enables shear stress 
endothelial stimuli to be increased, thereby enabling a microcirculation opening to be 
created in various organs of human body by means not only of conventional mediators of 
vasodilators such as nitric oxide, but also by means of other new vasodilators processing. 
6.1 Pulsatile suit 
In one aspect of the present method, blood is compressed from the outside of the body by 
means of a special suit referred to as a ‘pulsatile suit”, of the kind described in patents 
applications (WO/2008/000111) and (WO 2010/070018), which suit is used primarily to 
provide circulatory assistance to the right heart and secondarily as a device that makes it 
possible to obtain an overall hemodynamic improvement.  The pulsatile suit is composed of 
three layers and must be suitable for the postoperative situations and provided with 
security features as following: 
1. Inner layer made of elastic material (e.g. neoprene) to insure smooth tight massage like 
pulsed surge at the skin. 2. Middle sandwiched layer filled with gelatinous fluid, to alleviate 
the vigorous inflation/deflation, power induced by the driving force. 3. External layer made 
from tougher materials to keep the pulsed wave inwards toward the body. This part is 
equipped by security air releasing valve to prevent over inflation accident in case of 
mechanic defect. 4. Holes are previewed in the suit body, in order to facilitate medical 
administrations and prevent bedsores. 5. Layers thickness and design are modified 
according to age, body weight and indication of the patient. 6. The back portion of the trunk 
part of the suit (vest and belt) must not be inflatable in order to avoid any spinal, or back 
injuries. 7. Blood must be pulsed back from periphery towards the heart in a sloping 
progressive wave in longitudinal axis. Except at the chest part, pulsations must be started 
backward - forward towards the front, in a horizontal axis in such a manner to increase 
venous return within respect of the respiratory movement. 
Naturally, this pulsatile suit has detachable parts and may take on various forms such as a 
hood, a pair of trousers, a jacket, a glove, a boot, or a sock. The parts could be reassembled 
together in one unit and wrapped tightly around the patient body through straps and 
zippers, as shown in (Figure 6) and as patents descriptions. 
Figures 12 show such suit covering the bottom portion of the human body, which the 
therapist (doctor, nurse, or even the patient) can put into place without effort. The suit may 
be connected directly to an external pump, it may be actuated by the therapist himself or 
herself. 
The structure serves advantageously to guide the pulsations it generates, progressively in 
the venous return direction. It thus constitutes a circulatory assistance device for the right 
ventricle (RVAD). 
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Fig. 6. Pulsatile suit CAD 
6.2 Pulsatile tube 
In another of its aspects shown in (Figure 7), the method implements at least one specific 
“pulsatile pipe” that serves to impart pulses to columns of blood, and that is preferably used 
in the context of providing circulatory assistance to the left ventricle (LVAD). Such a pipe is 
described in particular in patents applications (WO/2008/000110) and (WO 2010/066899). It 
may form part of a pulsatile medical kit that also includes a conventional pump (with or 
without oxygenator) placed at one end of the pipe, and an aortic cannula is placed by 
surgeon as close as possible to the patient’s aorta. It is preferably prefilled in its intermediate 
space with an inert fluid such as helium, CO2, etc. This diminishes the risk of embolism 
since the gas initially present in the pipe is discharged outside the circulation. In addition, 
the pressure forces required for operating the pulsatile device are reduced.  It can readily be 
understood that this device is invasive to a very small extent. It generates pulsations in most 
effective manner and it is very easy to implement. It may be put into place surgically via a 
mini-incision or via a percutaneous approach and then synchronized with the patient’s 
electrocardiogram. 
www.intechopen.com
 “Flow and Rate”: Concept and Clinical Applications of a New Hemodynamic Theory 31 
 
1= Flexible inner tube; 2 = Rigid external tube; 3 = Intermediate chamber; 4 = Ports; 5 = Connectors 
Fig. 7. Disposable pulsatile tube (pipe) 
A disposable double lumens' tube, which is designed according to the principles of the 
“Bernoulli” 3rd equation: propagated pulsatile impacts transferred from the intermediate 
chamber (blue color), would move up the stagnant fluid boundaries' layers at the inner 
flexible tube (grey color), and push them towards the center in a mater to diminish the 
traumatic effects of blood and its components. Both tubes (inner & external) are sealed 
together at their extremities creating a sandwiched space between them with double central 
orifices connected to a pulsatile console. The tube is adaptable to a conventional CPB arterial 
line circuit through two standard connectors wedged at each end of the inner tube.  
Practically, circulatory perfusing systems create a state of momentum energy losses that could 
be identified in 6 main zones (Z0-Z5) (Nour S 2008), as follows (Figure 8): (Z0) it represents the 
pre-oxygenator zone, where momentum energy losses depend on types of driving forces (e.g. 
(e.g. roller or centrifugal pump) to be deleted as well as the oxygenator, which is a major 
constant site of energy losses; (Z1) it is the zone downstream to the oxygenator, where energy 
losses depend on circuit conduit types (length, width, materials) and fluid viscosity; (Z2) it is 
represented by the pulsatile tube wedged  at the arterial perfusion line between the oxygenator 
and aortic cannula; (Z3) it represents the pre-aortic cannula zone, which is the first effective 
pulsatile zone;  (Z4) it represents the aortic cannula zone, where the effect of convergent (at the 
entrance) and divergent (at the tip) energy losses plays an important role (Cutlera D 1999);  
(Z5) it represents the perfused tissues started from the tip of the aortic cannula, causing 
important divergent momentum energy losses.  
 
Fig. 8. Main momentum energy losses zone in a circulatory perfusion circuit 
Accordingly, the pulsatile tube receives the steady flow from (Z1) downstream to the 
oxygenator, till (Z2) where the homogenous pulsations from the inner tube’s walls move the 
stagnant laminar boundaries layers towards the center within total respect of Bernoulli’s 
principle, with less vortices and better conservation of blood components. 
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At (Z3) where the effective pulsatile flow starts, theoretically this pre-aortic cannula zone 
represents a convergent diffuser with low momentum energy losses at the entrance of the 
aortic cannula. Meanwhile, a short (Z3)’s distance is requested to reduce turbulence and 
vortices that might occur due to strong-pulsed flow within a fixed geometries' tube. 
Furthermore, the pulsatile tube serves to reduce the empty space between monitor system 
and the tube itself, thereby giving rise to optimized operation with minimum pulsatile 
pressure; it is thus possible to envisage miniaturizing the device and correspondingly 
reducing the energy needed for its operation. 
As seen in (Figure 12) a pulsatile pipe may be placed between the left subclavian artery and 
the right subclavian vein. 
6.3 Pulsatile catheter 
Another aspect of the present method comprises a “pulsatile catheter” comprising a 
conventional catheter that is surrounded by an inflatable element over a portion of its length 
(Figure 9). Such a catheter is disclosed in patent applications (US/2011/021987) and (WO 
2009/136035). 
 
Fig. 9. Intravascular shear rate enhancement device 
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According to (Figure 9), the invention relates to a device for creating a pulsating inflation of 
an inflatable component (11) of a catheter (8), comprising: a bag (1) that can be filled with 
fluid (2); a bag compression means (5) capable of compressing said bag (1) in a pulsed 
manner; and a connection means (3) connecting said bag (1) to said inflatable component 
(11) of the catheter (8) and allowing the fluid (2) to move between said inflatable component 
(11) and said bag (1). 
Advantageously, the inflatable element in place around the catheter presents in the deflated 
state an outside diameter that is less than that of the remainder of the catheter. Naturally, 
the inflatable element is connected to external inflation means suitable for generating 
pulsations during inflation. The device advantageously makes it possible to avoid 
excessively enlarging of the point where the catheter is inserted into a blood vessel. 
Such a device is used in particular for PAH with increase in the afterload of the right 
ventricle (right ventricular failure); the catheter is placed in the trunk of the pulmonary 
artery by a percutaneous venous approach, preferably in association with a pulsatile suit. 
6.4 Pulsatile console 
An example of the pulsatile console (Figure 10), is described in patent application 
(US 2011166515) that console is very simple in design and easy to use. The console enables 
determined pulsatile pressure to be created and applied to a pipe, a catheter, or ay other 
equivalent means. A simple source of fluid under pressure such as a bottle of an inert fluid, 
or of liquid under high pressure constitutes the continuous source that is transformed into a 
pulsatile source by the pulsatile console as disclosed therein. 
 
 
 
Fig. 10. Portable pulsatile console (Tu-Master). 
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The invention relates to equipment for applying a determined pulsatile pressure to a 
medical device, comprising: a withdrawing means (2) designed to withdraw fluid from a 
source of fluid in continuous flow at high pressure; a conversion means (3) designed to 
convert said fluid into a fluid in a pulsatile flow at low pressure; at least one application 
means (105) for applying said fluid, as a low-pressure pulsatile flow, to said medical device; 
and a means (104) for removing said fluid. 
6.5 Smartcan  
According to yet another aspect of the present method, a secure and almost non-invasive 
connection is provided between the patient and external mechanical systems for providing 
circulatory assistance (Figure 11). This aspect may be achieved by a device of the kind 
described in patent application (WO 2011/089162). 
 
  
 
Fig. 11. The Smartcan conduit device 
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That device entitled the “Samartcan”, makes it possible advantageously to group together 
all of the tools that make it possible to obtain a cardiovascular approach that is effective, 
fast, safe, and inexpensive. Thus, the tool enables a single operator, makes it possible to 
avoid all of the traditional steps such as incision, suture stitches, purse strings, etc. That 
simplifies the operation. Operating costs are thus significantly reduced. 
Such a tool may be put into place and moved with assistance and remote guidance, e.g. 
echocardiography. This avoids blind guidance under the patient’s skin for connecting the 
patient with an external circulatory assistance machine as with prior art methods. Such a 
connection gives rise to complications for the patient such as infections, hemorrhages, 
problems of closing the chest, etc. 
In an advantageous manner, such a tool can be used as an aortic cannula, a cardiac cannula, 
a vascular catheter, or indeed as tubing for cavity drainage. 
Such a tool, and more precisely the body of the device, is preferably prefilled with a liquid 
such as heparinized serum in order to reduce the risks of gaseous embolism and in order to 
shorten operating time. 
In a novel and advantageous manner, the distance between such a tool and the patient is 
very small. In other words, the distance between a circulatory assistance machine (CAD) 
and the puncture sites (on the patient) is very short; in particular when implantation is 
performed close to the subclavian artery. This characteristic greatly reduces the energy 
losses that are inherent to existing devices. 
The present invention relates to a single-use device to be used in surgery each time that a 
vascular approach by means of cannulation or catheterization is deemed indispensable 
(cardiopulmonary bypass, anesthesia, emergencies, resuscitation), particularly during cardiac 
surgery or interventional cardiology. Said novel device substantially includes a body (5), a 
sealing system consisting of two inflatable diskettes (4), a control connector for inflating and 
deflating the diskettes (4), a tubular unit (6) and a flexible guide (1). Upper right panel: shows 
a Smartcan with folded (G2) and unfolded (H2) external diskettes. Lower right panel: shows 
the Smartcan manually controlled guide wire before (E) and after penetrating a blood vessel 
(F). Left panel global schema of the Smartcan (A) and the proximal end (B) with the intraortic 
obstructive dikette (2), the cardioplegia delivery holes (3). 
6.6 l’Orthèse cardiaque 
According to another US patent application in pending, the various devices (pulsatile pipe, 
suit, and catheter, in particular) implemented in the present disclosure are synchronized 
together or separately as a function of the patient’s hemodynamic parameters. 
It relates to a novel therapeutic technique and method of providing mechanical circulatory 
assistance using a CAD that is minimally invasive. The CAD improves hemodynamics and 
microcirculation, and restores the endothelial function when it is insufficiently stimulated, 
particularly for a patient suffering from congestive heart failure (CHF). 
The device complies with the patient’s hemodynamic parameters as a function of breathing 
frequency and cardiac rhythm. Heart rhythm is detected by the electrocardiogram or by 
pacemaker as a function of variation in arterial pressure and/or in systemic and pulmonary 
resistances. 
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Synchronizing the pulsatile suit, thereby increasing venous return (preload) and reducing 
afterload, needs to be performed without hindering the frequency of breathing and without 
increasing central venous pressure above 16 mmHg. The pulsatile frequency of the suit may 
be less than the cardiac frequency of the patient (one-third to two thirds of the heartbeat). 
1
2
3
4
5
 
Right panel: l’orthèse with complete suit (full throttle option); left panel: l’orhèse with bottom trouser; 
1= pulsatile pipe set; 2 = left subclavian artery tip; 3 = right subclavian vein tip; 4 = arrow defines 
intraseptal drainage; 5 = pulsatile trouser set; 14 = vest; 15 = sleeves. 
Fig. 12. l'Orthèse Cardiaque 
In contrast, the pulsatile pipe associated with the patient’s electrocardiogram may be 
synchronized with cardiac rhythm and the pulsatile catheter may be faster than heart rate. 
In particular, the devices and methods of the present CAD avoids problem associated with 
blood circulation through two well-separated circuits (systemic and pulmonary) that are 
constituted by the vessels and arteries of the patient and by the mechanical circulatory 
assistance device (s). 
All of those pulsatile means enable variations in blood pressure to be created in vessels in 
application of the physical laws that apply to non-Newtonian fluids. They allow stagnant 
blood to be moved in compliance with Bernoulli’s law, i.e. from the walls towards the 
insides of the vessels. This therefore gives minimizes the traumatic effects on erythrocytes. 
When the heart pump, and in particular the left ventricle, is to be relieved (unload), the 
practitioner will use a Smartcan device in a version that enables an incision via the tip of the 
left ventricle or a left intra-atrial transeptal incision. 
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Similarly, when regular pulsations are to be produced and diffused close to the aortic root, 
the same device may be inserted as an arterial perfusion cannula in the root of the aorta or 
in the subclavian artery via a percutaneous approach or by echocardiographic guidance. 
Figure 12 shows a patient fitted with a pulsatile suit that covers the bottom portion of the 
body; in addition, a pulsatile jacket is placed around the patient’s thorax and pulsatile 
sleeves are placed on each of the patient’s upper limbs. In this embodiment of the invention 
a pulsatile pipe is placed between the subclavian artery and the subclavian vein. 
Furthermore, the present CAD is suitable for managing various types of heart failure, 
regardless of the right or left etiology. 
On the right heart, by putting pulsatile suit into place, the device makes it possible to reduce 
the stagnation of venous capacitances; by implementing a pulsatile catheter, it is possible to 
reduce the pulmonary afterload. 
On the left heart putting a pulsatile pipe into place enables physiological pulse pressure to 
be maintained and directly serves to improve overall hemodynamics by reducing systemic 
vascular afterload. 
Thus, the methods and devices according to the present disclosure may be defined as a 
circulatory orthosis, as opposed to prosthesis. Unlike orthotopic transplantation, the present 
disclosure makes it possible to keep the patient’s heart in place, thus allowing the patient to 
wait in relative comfort for a histocompatible donor. 
The present method provides bridging treatment prior to transplantation, thereby 
improving prognosis and morbidity by restoring patient’s hemodynamics. As a reminder, 
present-day mortality is higher for right ventricular failure it lies in the range of 65% to 95%. 
The present disclosure makes it possible to restore the endothelial function progressively by 
maintaining quasi-physiological shear forces on the endothelium; consequently, there is a 
significant improvement in the function of myocardium, thus making it possible avoid 
subsequent transplants. 
The present disclosure provides and approach that is invasive to a very small extent, since it 
avoids risky surgical acts, in particular, the invention avoids sternotomy and/or 
thoracotomy which can be put off until subsequent transplantation. 
The devices and method of the present disclosure thus makes it possible to cope with the 
shortage of donor and with the numerous problems that are associated with antirejection 
treatments. 
In addition, the present CAD is adapted to all age categories, from newborns to patients of 
great age and/or patients that are most clinically fragile. 
7. Experiments 
These devices were evaluated in vitro, as well as with clinical volunteers. The in vivo study 
was approved by the Animal Research Facility at Sun Yat-Sen University and conformed to 
the Guide for the Care and Use of Laboratory Animals (NIH Publication No.85-23, Revised 
in 1996). In original pediatric animal models of acute cardiogenic shock state, created in 
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piglets. We have avoided any premedication or any prophylactic medical support that may 
interfere with the endothelial function (e.g. atropine, -blockers, etc.). Only mechanical 
cardiac support was provided with the evaluated device compared to traditional therapies 
in control groups. The clinical volunteers were medical doctors included the author. 
7.1 Evaluation of the pulsatile tube device 
Perfusions of the circulatory system with devices like the cardiopulmonary bypass (CPB) 
and CAD disturb endothelial shear stress (ESS), which is responsible for the post-
cardiotomy syndrome, increasing liabilities of clot formation, bleeding, disseminated 
syndrome, etc (Bick et al., 1976)) (Abshire, 2009). This endothelial dysfunction syndrome is 
most probably occurred due to steady flow, foreign surfaces and the severe momentum 
energy losses. To overcome these side effects different therapeutic strategies are currently 
applied (Nour S, 2003), such as: a) pharmacological supports using antifibrinolytic (Cooper, 
2006), inotropes, vasodilators, platelets, etc. (Nardell, 2009), but with some side effects as 
well (Ishida, zt al., 2004); b) normothermia: that becomes more practiced in CPB with some 
proven advantages over hypothermia (Pouard, et al., 2006), which may be explained 
because blood is nearly Newtonian at 37.2°C (Box, et al. 2005). Meanwhile, the benefits of 
normothermia on myocardial protection and microcirculation improvements remain 
controversial (Rastan, et al., 2008), as the myocardium is already protected with doses of 
cardioplegia, while the perfusion of microcirculation is more or less helped by the Fahraeus-
Lindqvist effect due to hemodilution; c) total or partial absenteeism of CPB: that becomes 
popular with proven postoperative hemodynamic advantages, but it is still a challenging 
technique reserved for selected groups of patients (Shroyer, et al., 2009); d) pulsatile perfusion 
flow devices: in a matter to keep ESS some pulsatile CPB have proven advantages clinically 
and experimentally (Ündar, et al.,1999); (Undar, et al. 2006). Despite that, recent studies 
recommend the unphysiological steady flow (Voss, et al., 2010). This may be  explained by 
pulsatile CPB inadequate curves with the necessity of a double perfusion pumps system to 
compensate the oxygenators momentum energy losses. Instead associating an intra-aortic 
balloon pump (IABP) with a conventional CPB, as a cost-effective manner (Onorati, et al., 
2007), creates turbulent zones of vortices (Geankoplis, 2005), with vascular complications 
(Sanfelippo, et al.,1987) and controversial effectiveness ( Kadoi Y & Saito, 2000). 
Alternatively, the pulsatile tube represents a potential solution for those aforementioned 
CPB and CAD drawbacks 
The pulsatile tube device (Figure 7), was evaluated as a potential solution for these CPB and 
CAD drawbacks.  A device prototype was tested in vitro (a mock circuit) for energy losses 
studies and in vivo as a LVAD, also the tube prototype was associated in the in vivo study 
of a Bi-ventricular assist device (l’orthèse). 
7.1.1 In vitro study 
Materials and methods: a double lumen tube prototype as shown in (Figure 13), composed 
of: a) external polyvinyl chloride (PVC) (20 cm length, ½ inch diameter). b) Internal 
Polytetrafluoroethylene (PTFE) (18 cm length, 12mm diameter), reinforced with latex 
membrane (condom), as a protector against the PTFE micropore. c) 2 connectors (¼ inch) 
introduced at each end of inner tube and wedged to the PVC tube and securely sealed by 
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external adhesive straps and rings. A small animal ventilator (HX-300 TaiMeng 
Technologies Inc®), was applied as a pulsatile generator. 
 
Fig. 13. Pulsatile tube prototype (Dr. Nour) 
Mock circulation: with slight modifications from the literatures (Undar et al;, 2006), (Wang, et 
al., 2009), it was composed of (Figure 14): a roller head pump (Cobe® Cardiovascular Inc.), 
pediatric oxygenator (Sorin® Lilipput 2 Ecmo) and filter (Sorin® Group 
hemoconcentrators), primed with fresh piglet’s blood mixed with dextrane in concentration 
of  (2/3) and (1/3) respectively. A pediatric arterial line circuit, PVC tube (1.5 m length), 14 
FR aortic cannula (DLP® Medtronic, Inc.), venous line (1.5 m length) and simulating 
vascular resistance partial clamp, positioned downstream to the aortic cannula. 
 
1 = arterial perfusion line; 2 = pulsatile tube; 3 = aortic cannula; 4 = venous line; 5 = pressures lines; 6 = 
partial tube clamp (simulated resistance). 
Fig. 14. Mock-circulation: energy losses circuit (I) 
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7.1.2 Methods 
With variant pump flow rate (400, 600, 800 and1000 ml/min) and fixed pulsation rate (110 
bpm), we have compared circuit momentum energy losses during steady and  pulsatile 
flows in 3 different tube positions as following: 
 Energy losses I: the tube was positioned downstream to the oxygenator at 6 cm from the 
aortic cannula  (Figure 15-I). 
 Energy losses II: the tube was positioned downstream to the oxygenator at 150 cm from 
the aortic cannula  (Figure 15-II). 
 Energy losses III: the tube was positioned between pump and oxygenator (Figure 15-
III). This position conceptually simulates current devices of pulsatile CPB. 
Recorded pressure curves: first in a steady mode, then pulsatile by switching the tube’s 
generator on, were collected at 5 remote distances spots: up and downstream: to oxygenator 
(P1, P2); to tube (P3, P4) and to resistance (P5) which simulated a systemic arterial perfusion 
curve in patients. 
 
{I} = Pulsatile tube was positioned at 6 cm distance from aortic cannula; {II} = Pulsatile tube positioned 
at 150 cm distance from aortic cannula; {III}. Pulsatile tube wedged between roller pump and 
oxygenator. 1 = roller pump; 2 = oxygenator; 3 = arterial line; 4 = pulsatile tube; 5 = aortic cannula; 6 = 
resistance (tube clamp); 7 = venous line. P1, P2, P3, P4, P5 = perfusion pressures recording spots. 
Fig. 15. Mock-circulations with 3 different tube positions 
www.intechopen.com
 “Flow and Rate”: Concept and Clinical Applications of a New Hemodynamic Theory 41 
7.1.3 Statistics  
Continuous variables are expressed as the meanSEM. Comparisons between groups of 
independent samples were performed with student t-test hemodynamic data. P with a value 
less than 0.05 was considered statistically significant. GraphPad Prism® software was 
applied for all the statistical analyses in this study. 
7.1.4 Results 
As been resumed in (Table 5) and (Figures: 16 & 17), momentum energy losses were 
significantly increased with the pulsatile tube in positions: III and II, compared to position I. 
Furthermore, there were observations of an increased perfusion pressure at P5 from the 
initial P1 of those groups (II and III), signifying severe turbulence at the post-cannula zone, 
which theoretically, corresponds to patient’s aorta. There were minimum momentum 
energy losses with the steady flow in position. I, In contrast to positions II and III, there 
were important vortices with obstructive zones that created  a sort of  retrograde flow even 
before pulsations.  
Groups P1 P2 P3 P4 P5 
 NP (I) 32,5 ±1,3 31,3 ± 1,3 30,3 ± 0,5 30,3 ± 0,5 30,8 ± 0,5 
1 - NP (II) 36,3 ±1,3 37,8 ± 1 39,5 ± 0,6 38,5 ± 0,6 39,3 ± 0,5 
 NP (III) 40,3 ±1 42,3 ± 1 43 ± 0,00 42,3 ± 0,6 43 ± 0,00 
 Pm. (I) 34,5 ± 1,7 34,5 ± 1,3 33,5 ± 1,7 32,3 ± 1 31,8 ± 1 
2 - Pm. (II) 39,3 ± 0,5 40 ± 0,8 40,8 ± 0,6 40,5 ± 0,6 40,3 ± 0,5 
 Pm. (III) 43 ± 1,2 46 ± 2,2 46,3 ± 1,5 44 ± 0,8 44,8 ± 0,5 
 Ps. (I) 72 ± 3,5 81 ± 11 92,8 ± 4,9 98 ± 11,5 92,8 ± 5,6 
3 - Ps.(II) 97,3 ± 7 92,3 ± 6 90 ± 11,2 81,3 ± 7,5 82,3 ± 8,4 
 Ps. (III) 84,3 ± 6,6 79,8 ± 5,9 79,8 ± 5,5 69 ± 3,9 69 ± 4,2 
 Pd. (I) (-)4,4 ± 3,2 (-)6,5 ± 7,4 (-)13,6±11,7 (-)35,3±8 (-)33,5±13,3 
4 - Pd. (II) (-)1,1 ± 6,2 (-)7,8 ± 4,4 (-)0,8±9,4 5,6 ±8,4 13 ±3,2 
 Pd. (III) 0,5 ± 10 5,3 ± 5,3 7,5 ± 7,5 20,3 ± 3,8 20,3 ± 0,5 
 PP (I) 76,4 ± 3,4 87,5 ± 11,8 106,4 ± 15,9 133,3 ± 17,7 126,3±18,6 
5 - PP (II) 98,3 ± 7,9 1OO ± 10,4 100,3 ± 10,3 75,7 ± 15,4 66 ± 6,1 
 PP (III) 83,8 ± 9,2 74,5 ± 8,7 72,3 ± 12,6 48,8 ± 7,1 48,8 ± 4,7 
P = pressures in (mmHg); I,II,III: correspond to each different 3 circuits; NP: non-pulsatile pressure; Pm: 
mean pulsatile pressure; Ps: systolic pulsatile pressure, Pd: pulsatile diastolic pressure; PP: pulse 
pressure; (p<0.001). 
Pulse pressure was higher at P5 with position I, compared to position II & III. Pm was higher at P5 
compared to NP with position I. 
N.B. For further details please refer to the following experimental movies site: 
http://www.nourmd.com/ 
Table 5. Results of momentum energy losses, obtained in 3 different mock circuits. 
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Fig. 16. Perfusions curves obtained in vitro 
Perfusion curves (in mmHg) obtained at different circuit sites in 3 different pulsatile Tube 
positions: I, II, III close & distant from aortic cannula and pre-oxygenator respectively. The 
perfusion curve amplitude was significantly higher at P5 with position I, compared to 
positions II & IIII.   
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Energy losses 1 (upper panel) = pulsatile tube at 6 cm from aortic cannula; Energy losses 2 = pulsatile 
tube at 150 cm from aortic cannula; Energy losses 3 = pre-oxygenator pulsatile tube position. P1-P5 = 
distant circuit spots for perfusion pressure records (mmHg). NP= non-pulsatile; Pm = mean pulsatile 
pressure, Ps = systolic pressure; Pd = diastolic pressure; PP = pulse pressure. The pulse pressure (green 
color) was significantly higher with position I compared to positions II & III. 
Fig. 17. comparative steady and pulsatile flow perfusion curves obtained from 3 different 
circuits 
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Energy losses with different tube positions: I = pulsatile tube at 6 cm from aortic cannula; II = Pulsatile 
tube at 150 cm from aortic cannula; III = Pulsatile tube pre-oxygenator. P1-P5 = perfusion pressure 
records (mmHg) at main circuit energy losses spots. At P5 the pulse pressure (upper panel) as well as 
the systolic pressure (lower panel) were significantly higher in position I (red color) compared to other 
positions: II (blue color), and III (violet color). 
Fig. 18. Pulsatile flow pulse pressure (upper panel) and systolic pressure (lower panel8) 
7.1.5 Comments 
In this study, a steady perfusion flow was transformed successfully into pulsatile flow with 
a simple double lumen tube integrated into the arterial perfusion line of a conventional CPB 
circuit. According to our previous explanations (Figures 4 and 8), quantification of 
circulatory perfusion devices (CPB, CAD) depends on their momentum energy losses. The 
Bernoulli’s principles of energy losses could be applied with accuracy in vitro to quantify 
lumped models like CPB (Undar et al., 2007). In vivo vessels elasticity and vascular tone 
bring CPB quantification more closer to Newton’s law of shear stress as a major stimulant 
for endothelial NOS / resistances control.   
www.intechopen.com
 “Flow and Rate”: Concept and Clinical Applications of a New Hemodynamic Theory 45 
The resulted energy losses have proven the importance of the pre-cannula zone represented 
in position I by P4, compared to P3 and P2 with positions II and III respectively showing 
severe turbulent flow with  important vortices constitutions at this zone or (Z 3). Finally, the 
prototype by its position downstream to oxygenator could avoid an important obstructive 
zone of energy losses, which is almost constant with current CPB necessitating a double 
perfusion pump system and special low resistance oxygenator. 
Conclusion CPB induces momentum energy losses with severe endothelial dysfunction. 
Current pulsatile devices induce inadequate curves with high costs. Pulsatile tube, adaptable 
to a conventional driving system could induce homogenous, downstream and nearly 
physiologic pulsatile perfusion flow with low momentum energy losses. This is a cost-effective 
method,  promising low mortality and morbidity, especially in fragile cardiac patients. 
7.2 In vivo study (study in progress) 
The pulsatile tube device was tested as a left ventricular assist device (LVAD), in pediatric 
animal models (piglets) with acute myocardial ischemia. 
Materials and methods: in the pulsatile group: a prototype of a pulsatile tube was realized in 
the same manner as the in vitro study, then a short piece of 14 Fr. PVC tube was modified as 
a aortic cannula (Figure 19), in a matter to avoid the conastant energy losses caused by 
current cannulae length with narrow tips.  Same a small LV vent was attached to the other 
end of the tube. The whole system was connected to a pulsatile generator console (HX-300 
TaiMeng Technologies Inc®). In the control group: a centrifugal pump  (Sorin group 
Revolution ®), was connected to a standard aortic cannula (12 Fr. DLP®-Medtronic, Inc.) 
and apical vent (14 Fr. DLP®-Medtronic, Inc.). 
 
Tube (1) is connected to aortic cannula (2), LV vent (3) and console (4). 
Fig. 19. Pulsatile tube prototype used as LVAD 
1
2
3
4
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Steps Maneuvers 
1 Anesthesia / sternotomy / pericardectomy / dissection of great vessels. 
2 Insertion of an infundibular Swan-Ganz, aortic and apical pursestrings. 
3 Hemodynamic measurement / blood test data for Time 1 (T1). 
4 Heparin injection (2ml/kg) LAD coronary artery mid-term ligation (snugger). 
5 Time 2 (T2) = after 1 hr of ischemia without any medical support 
6 LVAD System switched on for 1hr. 
7 Time 3 (T3) data collection after 1 hr of assistance with LAD ligation. 
8 Removal of LAD snugger (coronary reperfusion + LVAD assistance) for 1hr. 
9 Time 4 (T4) data collection before animal sacrifice 
Table 6. Summary of the surgical steps 
Operative schema and steps of surgical protocol are resumed in (Figure 20) and (Table 6) 
respectively. 
 
 
(Ao=aorta, LV=left ventricle, vent. = ventilator) 
Fig. 20. Schema representing the pulsatile tube as a LVAD 
7.3 Results 
This ongoing study results showed better hemodynamic with lower cardiac enzymes in the 
pulsatile group compared to control (Figure 21) and (Table 7). 
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Upper panel: shows a massive myocardial ischemic zone after LAD ligation; Lower panel: ischemic 
zone after 15 min of  pulsatile tube assistance. 1 = Aortic cannula; 2= LAD snugger (permanent coronary 
occlusion); 3 = left ventricular apical vent; 4 = trans-infudibulum pulmonary artery & Millar right 
ventricular pressure catheters; 5 = right atrium pressure line. 
Fig. 21. Pulsatile tube as LVAD in piglet ischemic model 
 
Test T1 T2 T3 
P NP P NP P NP 
cTnT* 0.036 0.06±0.07 - 021±0.1 0.029 1.31±0.61 
CK-MB* 0.92 0.56±0.41 - 0.89±0.85 0.100 100±4 
PLT 351 487±100 - 245±128 47 80±3 
Htc 0.27 0.32±0.06 - 0.28±0.08 26 33±7 
Lac (v) 1.23 3.3±3.1 - 4.9±4.1 0.6 0.4±0.1 
Table 7. Biochemistry results: cardiac enzymes*; P: pulsatile group; NP: non-pulsatile 
(control group); Plt: platlets: Htc: hematocrit; Lac (v): venous lactate. T1: baseline; T2: 1h of 
ischemia; T3: after 2h of myocardial assistance.  
(2)
(3)
(4) (1)
(2)
(3)
(5)
(1) (4)
(5)
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Fig. 22. Pulsatile tube perfusion curve in vivo, as a LVAD in acute MI piglet 
The pulsatile tube's perfusion curve was nearly physiologic with complete discharge of the LV 
and unsynchronized with heartbeatt, as have been demonstrated on the operative movies. 
7.4 Operative movies of the pulsatile Tube ( LVAD): 
- Pulsatile as a LVAD associated with a conventional roller pump (Cobe® Cardiovascular 
Inc.):  http://www.nourmd.com/ 
- Pulsatile tube as a main LVAD, without any other associating driving systems: 
http://www.nourmd.com/ 
- Control group movie, LVAD by (Sorin Group Revolutionary centrifugal pump®): 
http://www.nourmd.com. 
7.5 Comments 
The exposed results proved the feasibility as well as the effectiveness of the pulsatile tube as 
a LVAD. These preliminary results have shown hemodynamic improvement and 
myocardial recoveries, lower cardiac enzymes in the pulsatile group, compared to control. 
This hemodynamic improvement was significant in the pulsatile tube group and despite the 
maintained coronary obstruction in a fragile pediatric model, with very poor coronary 
collaterals. Interestingly we’ve tested the tube alone without a perfsuion pump and LV vent, 
as an endocardial stimulator.  Myocardial recovery and macroscopic disappearance of the 
ischemic zone were obvious after few minutes (< 5min), of unsynchronized pulsations 
(please refer the attached movie). This was ended by severe vasodilatation and cardiac 
arrest. Currently, we are trying to overcome these drawbacks, particularly, the inner tube 
(PTFE) microporosity and vasodilatations, with a new generation of pulsatile tube 
prototypes. 
8. Evaluation of the pulsatile catheter device (in vivo) 
Prototype: a standard IABP catheter (8 Fr., 30 cc) was modified. Briefly, its original balloon 
membrane was peeled off and replaced with a small piece of commercial rubber balloon, 
secured and tied manually at each end of the catheter. This created an inflatable 
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compartment of 11 cm. The distal part of the prototype was connected to a 
cardiorespiratory monitor (BIOPAC® physiology monitoring system, ECG channel). For a 
pneumatic rhythmic driving force, it was attached to a small animal ventilator (HX-300 
TaiMeng Technologies Inc®). It was tested for leakage while pulsating in a heparinized 
saline bath. Once the prototype was inserted into the pulmonary trunk, the circuit inflation 
volume was adjusted (usually between 50-90 ml) to avoid right ventricular outflow tract 
obstruction. The ventilator was pulsed at a frequency of 110 cycles/min. The prototype 
device was tested in two animal model studies for acute MI and acute PAH as follows: 
8.1 Acute myocardial ischemia model 
(part of the results was presented at the 17th conference of ACTVS, Nour, 2009) 
Material and methods: Twelve piglets (8.3 ± 1.5 kg) were given either pulsatile (P: n=6) or non-
pulsatile (NP: n=6) nitrates treatment. Both groups underwent permanent left anterior 
descending coronary artery (LAD) ligation with a median sternotomy (Figure 23). After 1 h of 
ischemia, heparin was injected (150 IU/kg). In group P, a prototype CAD, driven by a small 
ventilator, was introduced into the pulmonary trunk and pulsated intermittently over 1 h at 
110 bpm, irrespective of heart rate (73 ± 16 bpm). In group NP, nitrates were given (7±2 
g/kg/min) for 1 h. Animals survived ischemia for 2 h in group P vs. 93±30 min in group NP. 
 
1 = Pulmonary artery (PA); 2 = pulsatile catheter fitting PA trunk; 3 = right ventricle (RV) inlet-outlet 
compartments; 4= infundibular site of pulmonary catheter insertion; 5 = arrows showing presumed 
passage of pulmonary eNOS (backward through coronary ostia and/or forward through systemic 
circulation); 6 = left ventricle (LV) inlet-outlet compartments; 7 = permanent ligation of the left anterior 
descending coronary artery distal to the second diagonal branch; 8 = interventricular  septum; 9 = 
cardiorespiratory monitor; 10 = pneumatic driving force. I = pulmonary eNOS primarily induced at PA 
zone with catheter pulsation; II = pulmonary eNOS natural passage through the left heart circuit; III = 
presumed pulmonary eNOS involvement in myocardial recovery most probably through 
microcirculation and/or the RV  interseptal coronary network. 
Fig. 23. Presumed mechanism and passage of induced pulmonary eNOS 
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With the macroscopic disappearance of infarction (Figure 24), group P exhibited improved 
hemodynamics (Figure 25) and significantly lower myocardial apoptosis (0.66±0.07) 
compared to group NP (4.18±0.27), (Figure 26). Vascular resistances (dyne.sec/cm-5.kg-1) 
were significantly lower (P<0.01) in group P vs. group NP: pulmonary resistance was 
119±13 vs. 400±42, and systemic resistance was 319±43 vs. 1857±326, respectively. 
Myocardial endothelial NO synthase mRNA expression (Figure 27), was higher in group P 
(0.90±0.09) than in group NP (0.25±0.04; P<0.01), probably due to endogenous pulmonary 
NO secretion.  
 
 
 
Left panel figure showing dark infarcted myocardial after 50 min of ischemia; right panel figure 
showing significant reduction of ischemic myocardial zone after 10 min of pulsation; 1 = left anterior 
descending coronary artery snugger; 2 = infundibular  site  of  the intrapulmonary pulsatile catheter 
insertion. 
Fig. 24. Macroscopic disappearance of the ischmeic zone in group P 
1
1
2
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Right panel showing the pulmonary vascular resistances index (PVRI) calculated from pulsatile group 
(P; red color) and non-pulsatile group (NP; blue color) at three predetermined time: T1= baseline; T2 
after 1H of shunt and T3= end of 1h therapy. at T1 (baseline) and the end (T3). PVRI (dynes.sec.cm-5/kg) 
were significantly lower (p<0.01) were significantly lower at T3 in group P compared to group NP. Left 
panel showing the cardiac output (CO) from both groups P and NP. CO (L/min) was with significantly 
improved at T3 in group P compared to group NP (p<0.01), in group P (red color) compared to group 
NP (bleu color). 
Fig. 25. Hemodynamics improvement with the pulsatile treatment in group P 
 
 
Fig. 26. Myocardial apopotosis (TUNEL test) 
Representative figures from both groups showing apoptotic cells manifestations (red arrows), 
from both groups: group P (left) and group NP (right). The apoptotic index (AI) in group P 
was significantly lower than that in group NP (P<0.01). 
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RT-PCR results shown with statistics, in which myocardial eNOS expression was significantly higher in 
group P (left) compared to group NP (right). (p<00.01). 
Fig. 27. Myocardial eNOS mRNA expression 
 
Left panels: samples from the non-pulsatile, nitrate treatment group (NP);  right panel: sample from the 
pulsatile treatment group (P). Notice the relatively well-preserved myocardial microstructure in group 
P. Bar scale on each graph equals one micrometer. 
Fig. 28. Myocardial microstructure visualized with transmission électron microscopy 
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8.2 Comment 
Decalogue of original observations emanated from the present preliminary study as follows: 
i. Hemodynamic improvement, with significant recovery of the myocardial contractility 
and cardiac output (CO), despite maintained coronary obstruction. This was obvious 
macroscopically, and confirmed by low myocardial apoptosis manifestation, and 
relatively well-preserved cardiomyocytes organelles in the pulsatile group P. 
ii. Intrapulmonary shear stress enhancement, that was induced successfully and for the 
first time according to literatures, as that was practiced with uncertain results, using an 
intra-aortic balloon pump (IABP) (Letsou et al. 1993). The uncertainty is probably due to 
differences between vessel geometries and catheters diameters, in addition the right 
heart side has specific morphological particularities that must be considered (Burton, 
1954), (Huang W & Yen RT, 1998).   
iii. Endogenous vs. exogenous nitric monoxide (NO): generally, NO has an important 
effects on the cardiovascular system as a potent vasodilator, inhibitor of platelets 
aggregation and myocardial contarctility (Jones SP & Bolli, 2006). Shear stress induces 
endogenous NO production by activating endogenous nitric oxide synthase (eNOS). 
(Chatzizisis et al., 2007), like during physical exercise Walsh et al., 2003). Also 
exogenously administered NO donors like Nitrates, can to be deleted induce eNOS 
(Ignarro, et al.,2002). Therefore, the study results showed that physiologically induced 
NO was superior to exogenous nitrates in acute IHD syndrome. 
iv. Microcirculation vs. collaterals, in group P, the increased expression of myocardial 
eNOS mRNA (Depre, et al. 1997); with fewer apoptotic cells (Mital, et al., 2002) could be 
explained by endogenous NO due to the intrapulmonary catheter pulsation. Meanwhile 
the exact mechanisms of action remain to be explored. However several conditions 
supported the role of microcirculation, as the subendocardial resistance vessels are 
more sensitive to mediators of vasodilatation and endothelium dependent dilators 
(Pelc, 1987). In consideration of the short biological lifetime of NO (Doherty et al., 1998), 
and the maintained coronary ligation, the chosen model is known for poor coronary 
collaterals, in addition to the immature myocardium in young pig model (Gorge, et al. 
1989). This may be explained by an undiscovered endothelial mediator(s) that 
improved myocardial microcirculation in the group P. in group P.   
v. Reperfusion injury syndrome to be deleted, interestingly the study results showed that 
immediate myocardial reperfusion might be unnecessary. The procedure, provides 
stabilization as well as myocardial and hemodynamic recoveries without the urgent 
need of reperfusion with the well known consequences of the reperfusion injury 
syndrome (Heinzel, et al., 2008). This was confirmed with our ongoing study, using an 
intrapulmonary catheter device induced percutaneously through the jugular vein. 
vi. Right heart vs. left heart endothelium, this study suggested that the right heart 
endothelium responded rapidly, to shear stress stimuli, compared to the left heart 
endothelium, which is most frequently, stimulated with devices like IABP and EECP, 
known for tolerance and long with long term effectiveness respectively (Pagonas, 2010). 
We found that the PA endothelium was hypersensitive; a few minutes of 
intrapulmonary pulsations were more than sufficient to drop systemic and pulmonary 
pressures. At the beginning of our trials,  have observed severe vasodilation with 
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continuous  intrapulmonary catheter pulsation (2 animals were expired). We then shifted 
from continuous to intermittent pulsation controlled by hemodynamic readings (5-
10min pulsation) interrupted by pause intervals (10-15 min). 
vii. Venous vs. arterial approach, the systemic arterial approach is most commonly 
practiced in IHD management, typically with IABP and/or PCI procedures. However, 
these require specific operative environments with high risks of risk vascular 
complications (Busch, et al. 1997); (Dangas, et al., 2001). Instead, the study provides a  
safer and cost-effective venous approach for IHD management that could be done by an 
ER therapist without the need to specific cardiac centers facilities.   
viii. Diastolic CAD synchronizations vs. unsynchronized pulsatile catheter, contrarily to 
present synchronized cardiac assist devices (CAD), like the IABP, EECP, etc., we believe 
that unsynchronized catheter pulsation simplifies and broadens its application as an 
efficient cost-effective method for IHD management. Recorded pressure curves showed 
that the delivered catheter pulsation was faster than the heart rate; Nevertheless, it did 
not disturb right ventricular hemodynamic or obstruct the outflow tract. 
ix. Suitable for almost all kinds of myocardial ischemia, as been observed, hemodynamic 
stabilization could be achieved after a few minutes of device pulsation without any 
pharmacological supports. Positioned inside the PA trunk, the device can reduce 
pulmonary afterload without jeopardizing preload in case of RV ischemia. Its small 
dimensions allow applications in pediatrics and other cases of non-atherosclerotic IHD 
(e.g. congenital, spasm, or vasculitis, induced MI. Moreover, in preconditioned (Bolli R, 
2001), hibernating, stunned myocardial or permanent ischemic lesions (Vroom MB & 
van Wezel, 1996), long term intermittent intrapulmonary or intracoronary sinus 
catheter pulsation could restore myocardial tissues and dysfunctional endothelial 
coronary lesions. 
x. The pulsatile catheter device  vs. CAD, compared to current  CAD drawbacks, an 
autonomous small catheter driven by a portable or implantable pacemaker-like 
generator, could be safely inserted into the circulatory system of any patient or chosen 
vessel, including arterial, venous or umbilical. And most probably, it could restore 
atherosclerotic endothelial lesions and endothelial dysfunction with the pulsatile 
catheter insertion into the intrapulmonary or intracoronary sinus in coronary 
atherosclerosis or into the main lumen of a diseased systemic artery (e.g. carotid, renal, 
femoral, etc.). An enhanced external counter pulsation studies in animal models have 
shown that regular application of endothelial shear stress stimuli could improve 
conditions related to atherosclerotic endothelial dysfunction (Zhang, et al., 2007). This 
could be a supportive argument for the concept. 
In summary, An intrapulmonary pulsatile catheter device could improve hemodynamics 
and recover acute myocardial ischemia efficiently, compared to nitrates. This could be 
induced with an appropriate intrapulmonary catheter device, adaptable to vessel 
geometries, regardless of coronary occlusion and irrespective of the heartbeat. The 
procedure represents an innovative and cost-effective method for IHD management, 
particularly through an intravenous percutaneous approach (ongoing study). 
Operative movie site: http://www.nourmd.com. 
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9. Acute pulmonary arterial hypertension* 
Pulmonary arterial hypertension (PAH) is a dysfunctional endothelium disease with 
increased pulmonary vascular resistances (PVR) and poor prognosis. Current therapies are 
still insufficient. Alternatively, we propose a the pulsatile catheter device as a more effective 
for PAH management compared to traditional treatments. 
Material and Methods: Twelve piglets (10.3 ± 3.8 kg) were given either intrapulmonary 
pulsatile (P: n=6) or non-pulsatile (NP: n=6) Tadalafil treatment. After median sternotomy 
and heparin injection (250 IU/kg), both groups underwent aorto-pulmonary surgical shunt 
during 1 h then removed (Figures 29 and 30). Over a second 1 h period: in group P, a 
catheter prototype, driven by a small ventilator, was introduced into the pulmonary trunk 
and pulsated intermittently at 110 bpm, irrespective of heart rate (90.6±10.74 bmp). In group 
NP, Tadalafil were given orally (1 mg/kg). 
 
 
 
1 = pulmonary artery branch; 2 = pulmonary artery trunk; 3 = inflated balloon in place; 4 = infudibular 
snugger; 5=catheter shaft; 6= cardiopulmonary monitor; 7 = pulsatile driving system (small animal 
ventilator); 8 = right ventricular cavity. 
Fig. 29. Intrapulmonary pulsatile system 
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Assembled shunt showing: 2 PVC limbs unequally cut with ½ cm; connected together with silicone tube 
and equipped with 2 stopcocks and pressure lines connectors, prefilled with heparinized saline and 
clamped ready before insertion. Aorto-pulmonary shunt in place with infundibular intrapulmonary 
artery pressure line  (white color). 
Fig. 30. Aortico-pulmonary “U” shape external shunt system. 
Statstics: Continuous variables are expressed as the meanSEM. Comparisons between 
groups of independent samples were performed with student t-test for eNOS and a 2-way 
ANOVA for hemodynamic data. P with a value less than 0.05 was considered statistically 
significant. GraphPad Prism® software was applied for all the statistical analyses in this 
study. 
Results: hemodynamic and cardiac output (CO) were significantly (p<0.05) better in group P 
compared to group NP: CO was 0.56±0.0.26 vs. 0.54±0.11 (L/min) respectively. Mean 
pulmonary artery pressure (PAP) was significantly dropped in group P compared to group 
NP: PAP was 9.6±2.97 vs. 32.25.07 respectively. Vascular resistances (dynes.sec/cm-5.kg-1) 
were significantly lower in group P vs. group NP: pulmonary resistance (Figure 31), was 
85±42.12 vs. 478±192.91, and systemic resistance was 298.8±172.85 vs. 1301±615.79, 
respectively. The endogenous NO synthase expression in PA segments with Western blot 
analysis was higher from group P (0.81±0.78) vs. (0.62±0.35) in group NP (p>0.05). 
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Fig. 31. Systemic and pulmonary vascular resistances indexes 
Upper panel: showing data of the systemic vascular resistances index (SVRI) calculated from 
pulsatile group (P; red color) and non-pulsatile group (NP; blue color) at three 
predetermined time: T1= baseline; T2 after 1H of shunt and T3= end of 1h therapy. at T1 
(baseline) and the end (T3). Lower panel: showing data of the pulmonary vascular 
resistances index (PVRI) calculated from pulsatile group (P; red color) and non-pulsatile 
group (NP; blue color) at three predetermined time: T1= baseline; T2 after 1H of shunt and 
T3= end of 1h therapy. at T1 (baseline) and the end (T3). Both SVRI and PVRI (dynes.sec.cm-
5/kg) were significantly lower (p<0.001) were significantly lower at T3 in group P compared 
to group NP. 
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Comment This study confirms the dominancy of the right heart over the left heart and 
hemodynamic through PVR 
The effect of intrapulmonary shear stress enhancement was immediate upon both PVR and 
SVR in the group P. The significant improvement of hemodynamic with rapid reduction of 
pulmonary pressure in group P compared to the  group NP, confirms the dominancy of 
shear stress-mediated endothelial function enhancement method over traditional therapies*.  
Also this confirmed what we have mentioned with the ischemic models regarding the 
hypersensitivity of the right heart side endothelium of the pulmonary artery compared to 
systemic arteries.   
Conclusions: Induced with an appropriate device, intrapulmonary shear stress-mediated 
endothelial function enhancement, provides a more effective nearly physiological therapy 
for PAH. 
* Abstract of the study concept was presented at the 16th conference of ACTVS - 
Singapore, Nour, 2008). Paper in press, submitted to the Pediatric Cardiology Journal 
(Nour, S 2012). 
Operative movies: http://www.nourmd.com. 
10. Evaluation of the pulsatile suit device 
This concerns the non-invasive devices (pulsatile suit) that were tested in vivo and healthy 
volunteers (the author and medical doctors colleagues).   
10.1 Animal model of acute RV failure* 
Cardiac assists devices (CAD) for right ventricular (RV) failure remain controversial with 
poor results. The purpose of this study was to evaluate a pulsatile suit CAD in an acute RV 
failure model vs. current therapies. 
Material and methods (Figure 32): twelve piglets, divided in two equal groups: pulsatile 
group P and non-pulsatile group NP. Acute pulmonary incompetence was created 
surgically through median sternotomy. Management started once severe RV failure 
observed (48.1±24.5 min): in group P, a pulsatile trouser, driven by pneumatic generator was 
pulsated intermittently at 40 bpm, irrespective of heart rate (104±27 bmp). Group NP, was 
treated with oral Tadalafil (1 mg/kg), IV fluids and adrenaline (0.3g/kg). 
Results (Figure 33 & Table 8): after 1 h of therapy, hemodynamic and cardiac output (CO) 
were significantly (P<0.05) better in group P compared to group NP: CO 1±0.2 vs. 0.7±0.2 
(L/min) respectively. Mean RV pressure (RVP) and pulmonary arterial (PAP) pressure were 
dropped in group P compared to group NP: RVP 16±6 vs. 24±2 and PAP 22±1 vs. 31±2 
(mmHg) respectively. Vascular resistances indexes (dyne.sec/cm-5.kg-1) were dropped in 
group P vs. group NP: pulmonary resistance was 174±60 vs. 352±118, and systemic resistance 
was 611±70 vs. 1215±315, respectively. Western-blot analysis of pulmonary arteries shown 
higher endogenous NO synthase (eNOS) expression  (p>0.5) in group P :0.90±0.71 vs. 0.66±0.52 
in group NP. 
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Fig. 32. Pulsatile trouser (intraoperative view) 
 
 
T1 
Group PAP RVP PVRI CO 
P 24±3 / 15±2 29±4 / 14±5 168±27 0.8±0.3 
NP 23±4 /15±3 34±3 / 7±2 182±42 0.9±0.1 
T2 
P 41±2 / 27±3 43±2 / 16±5 314±17 0.7±0.2 
NP 42±3 / 25±2 46±2 / 12±3 385±51 0.7±0.2 
T3 
P 27±2 / 17±2 28±2 / 6±3 174±27 1±0.2 
NP 39±3 / 23±2 42±1 / 7±1 352±52 0.7±0.2 
 
Table 8. Therapeutic response of the right heart hemodynamic parameters (Trouser vs. 
TadalafilTM): Systolic and diastolic pressures (mmHg) of the right ventricle (RVP) and 
pulmonary artery (PAP); PVRI: pulmonary vascular resistances index (dynessec/cm5/kg); 
CO: cardiac output (L/min); T1: baseline; T2: nearly 1 h after pulmonary valve disruption; 
T3: end. P: pulsatile group; NP: non-pulsatile group; (p<0.05). 
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P: pulsatile group (red color), NP: non pulsatile group (blue color); left panel showing cardiac output 
panel showing pulmonary vascular resistances index (PVRI); right panel showing cardiac output (CO) 
results obtained from both groups P and NP in three. Data were obtained from both groups (P & NP) at 
three predetermined time: T1= baseline; T2: nearly 1 h after pulmonary valve disruption and T3= end of 
1h therapy. CO (L/min) was significantly improved (p<0.05) at T3 in group P compared to group NP. 
PVRI (dynes.sec.cm-5/kg) were significantly lower were significantly (p<0.01) lower at T3 in group P 
compared to group NP. (Two ways ANOVA test) 
Fig. 33. Hemodynamic figures 
*Paper was submitted to the Asian Cardiovascular & Thoracic Annals Journal (in press 
Nour, S 2012). 
Operative movies: http://www.nourmd.com. 
10.2 Clinical volunteers (study in progress) 
10.2.1 Mask 
Pulsatile mask was tested in healthy volunteers (n=8) from both sex (age:19-68 ys), subjected 
to 20 minutes of low pressure (0.2-0.6 bars) pulsatile mask, synchronized with diastolic heart 
rate. Statistics: Continuous variables are expressed as the meanSEM. Comparisons between 
groups of independent samples were performed with student t-test hemodynamic data. P 
with a value less than 0.05 was considered statistically significant. GraphPad Prism® 
software was applied for all the statistical analyses in this study. 
Results: hemodynamics and cerebral blood flow was significantly improved (p<0.05), as 
manifested by Doppler flow measured at the common carotid artery (Figure 35): carotid 
output: 246±41.73 vs. 294±50.42 (ml/min), and velocity 18±2.4 vs. 21±2.8 (cm/sec). 
Microcirculation measured from the tip of the nose (Perimed®-PeriScan 3 System), was 
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45.5±14.6 vs. 89.2±31.1 (p<0.001) with unsynchronized mask pulsations (Figure 34); and 
from the mandibular angle (measured with Perimed® - PeriFlux System 5000), was 28±12.5 
vs. 87±35.2 (p<0.05), with synchronized mask pulsations (Figure 35). 
 
 
 
 
Upper panel, showing mask device inflated and connected to a generator equipped with a set for 
hemodynamic measurements (ECG, BP, SaO2); lower panel showing cutaneous microcirculation 
measured from the tip of the nose at T1: baseline; T2: after 15 min of low pressure pulsation (0.2-0.4 bar) 
unsynchronized with heart rate; T3: by the end after 30 min of pulsation. T4: 30 min after the end. 
Fig. 34. Pulsatile mask improving facial microcirculation 
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Upper panel carotid flow measured by echo Doppler; lower panel: facial microcirculation (from the 
mandibular angle) 
T1: baseline; T2: after 20 min of pulsations 
Fig. 35. Synchronized pualstile mask results 
N.B. interestingly the microcirculation’s flow shown in (Figure 34), was rapidly increased 
after 15 min of pulsations, then dropped slightly to pass in plateau over the second 15 min 
of stimulation. This proves the physiological effect of the device that does not stun 
endothelial biology, allowing self-cellular regularization in response to induced endothelial 
vasodilators mediators and unlikely to exogenous NO donors vasodilators (e.g. nitrates). 
Movies demonstration of the pulsatile mask: 
http://www.nourmd.com. 
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10.2.2 Trouser 
Pulsatile trouser, that covering almost the trunk, was tested in healthy adult volunteers (the 
author and medical colleagues) (n:6), were subjected to a  low pressure (1.2 bars) fixed 
pulsations (60 bpm) and without synchronization of heartbeat (72± 17 bpm). Results (Figure 
36); after 20 min of pulsations, the peripheral microcirculation was measured with laser 
flowmeter (Perimed®-PeriScan 3 System) at the tip of the finger was significantly improved: 
93.5±31.3 vs. 222.4±35.8 (p<0.003). 
 
 
Upper panel: pulsatile trouser’s  prototype; lower pannel: increased peripheral microcirculation, 
measured at the tip of the right index (laser flowmeter: Perimed®-PeriScan PIM 3 System) 
Fig. 36. Hemodynamic results after 20 min pulsation in 6 volunteers 
Movie demonstration http://www.nourmd.com. 
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11. Evaluation of the Biventricular assist device “L’Orthèse cardiaque” (study 
in progress) 
11.1 In vivo  
The device was tested in an acute ischemic biventricular failure (piglet). This was created by 
mid ligation of the LAD, and elecrocauterization of the RV coronary artery branches, for 
details refer to the attached operative movies site. The preliminary results shown better 
hemodynamic responses with the biventricular assist device combing the pulsatile tube as a 
LVAD and the pulsatile trouser as RVAD (Figure 36).   
 
Fig. 37. Biventricular  CAD (l’Orthèse cardique) in ischemic model (piglet) 
Operative movies: http://www.nourmd.com. 
Comment: in this study the device (l’Orthèse cardiaque) was tested as well in total cardiac 
arrest followed and acute ischemic biventricular failure and cardiogneic shock. The device 
was successfully capable to circulate the stagnant blood columns within the respect of  the 
biophysical conditions of each heart circuit biophysiological conditions (please refer to the 
attached movie). The study pending new pulsatile tube constructions. The object is to 
maintain circulatory flow dynamics and cellular metabolism in case of acute biventricular 
failure until improvement of hemodynamic or arrangement for  heart transplants with 
compatible donors in nearly physiological condition. 
11.2 In clinical volunteer 
The pulsatile trouser was indicated in a CHF patient, (a medical consultant from the UK), as 
an ultimate therapeutic option, according to a consensual patient’s request. The patient was 
short-listed for both heart and kidney transplant, then been removed due to severely 
deteriorated hemodynamics:  EF ≈ 15%, systolic pulmonary arterial pressure >65 mmHg, 
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and elevated BNP (1100 pg/ml). He was on renal dialysis (6 days/ week), chronic 
constipations and oxygen sleep dependent.    The pulsatile trouser was applied for 2O 
minutes daily, in a posture position* with fixed frequency (40 bpm), irrespective of patient’s 
pacemaker (78 bpm) and low inflation / deflation pressure (1.4 bar). The patient recovred 
regular bowl, and became less dependent on oxygen during the first week of treatment. 
After two months there was hemodynamic improvement: EF≈ 20%; systolic PAP ≈ 41mmHg 
and BNP ≈ 500 pg/ml. The patient reintegrated the NHS transplant program. Despite, 
hemodynamic improvement, the procedure was interrupted because a cholecystectomy was 
urgently, needed for biliary lithiasis, which may promote to shower pancreatitis with the 
trouser pulsations.  
*N.B. In CHF patients, it is preferred to apply trouser therapy in a posture position, rather 
than supine position to amplify the gravity effect as an enhancement factor of shear stress 
with more voluminous columns of venous capacitance.  
Movie demo: http://www.nourmd.com. 
11.3 Comment 
These aforementioned preliminary results have proven the feasibility of the concept as a 
promising therapeutic approach for CVD. On other word, proven the efficiency of the right 
heart endothelial reservoir as a physiological therapeutic backup compared to optimum 
traditional therapies in addressing acute cardiogenic shock state. 
The pulmonary endothelium, stimulated with a small size pulsatile catheter that can be 
introduced intravenously and percutaneously, open a new era in cardiology as almost all 
types of ischemic heart disease as well as pulmonary arterial hypertension (PAH). 
Macroscopic disappearance of the ischemic zone confirmed with low myocardial apoptosis 
and that despite permanent ligation of the coronary artery means improved hemodynamic 
is more related to open myocardial microcirculation in neonate animal model known with 
poor coronary collaterals. 
A significant drop in the pulmonary vascular resistance was the key of hemodynamic 
improvement. This can be induced with the proposed pulsatile systems after short period of 
intermittent shear stress-mediated endothelial function stimulations at the splanchnic and 
hepatic venous capacitance, or at the pulmonary artery, and irrespective to heart rate. 
Pulsatile suit concept results that have been obtained in volunteers also open a new era of 
therapeutic approach in nearly all types of endothelial dysfunctions pathogenesis as follows: 
with (Type A), endothelial dysfunction with heart disease patients; in Type B, with 
endothelial dysfunction and normal heart function (e.g. diabetic, systemic arterial 
hypertension, PAH, erectile dysfunction, etc); and Type C, as prophylactic in healthy 
individuals, liable for endothelial dysfunction pathogenesis (Astronauts, bedridden, etc) as 
well as a circulatory hemodynamic physiological stimulus (e.g. athletics, anti-aging, etc). 
The pulsatile mask can improve the cerebral circulation directly through the cavernous 
venous systems, and systematically through the jugular vein system, current studies show 
enhancement of the retinal artery flow as well as diameter, which ca be effective in treating 
early neurodegenerative diseases and stroke patients. 
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This improvement is observed at points remote from the pulsating zone, i.e. where the suit 
was being worn. 
A clear improvement in microcirculation has also been observed at the fingertips as a result 
of putting a pulsatile suit (trouser) on the bottom portion of a patient’s body as shown in 
(Figure 36). 
Practically, delivery of shear stress stimuli at the compliant pulmonary artery (PA) zone  
(zone5), can be induced according to the Bernoulli’s principles with a small size pulsatile 
catheter adaptable to the pulmonary trunk geometries for shear rates enhancement at the 
inner boundaries layers, irrespective of heartbeat without obstructing the right ventricular 
outflow tract. Meanwhile at the superficial venous capacitance (zone1) shear stress 
enhancement could be achieved externally with the pulsatile suit. 
At the left heart side, an endothelial shear stress will be induced by the pulsatile tube. The 
pulsatile tube could adapt whether a conventional CPB or CAD, provides a nearly 
physiological pulse pressure with lowest momentum energy losses, particularly in 
association with the Smartcan. It will considerably reduce the distance between CAD and 
the perfused artery (Z3).  
Similarly, an improvement in the microcirculation of the myocardium has been observed in 
an ischemic model by permanent ligation of the left anterior descending coronary artery 
(LAD), after applying shear forces generated by pulsatile catheter inserted in the pulmonary 
artery forming part of the right circuit of the heart. 
Given the very short lifetime of nitric oxide, it cannot reach zone that are remote from the 
site where it is secreted, since it is necessarily absorbed by hemoglobin before reaching said 
remote zones. Thus, it has been found that at least one mediator mechanism other than 
those that are already known and secreted by the endothelium is capable of triggering the 
opening of microcirculation. The devices and methods of the present concept 
advantageously enable such secretion to take place. 
As a priority, assistance should be provided to the right portion of the heart. It is known that 
the right heart “dominates” the left heart and controls hemodynamics by pulmonary 
resistances (Nour S 2008). Isolated ventricular assistance, on the left or right, can then be 
envisaged in accordance with the present disclosure; and after that assistance for the left 
heart. 
The method makes it possible to restore the endothelial function progressively by 
maintaining quasi-physiological shear forces on the endothelium; consequently, there is a 
significant improvement in the function of myocardium, thus making it possible avoid 
subsequent transplants. 
Alternatively, the pulsatile catheter prototype, when applied in the clinic, could be 
implanted into the pulmonary artery through a central venous line (ongoing study), in 
hospital settings, it could be connected to a small portable-implantable driving device. 
Patients with catheter device set implants would benefit from real-time hemodynamic 
measurements and simultaneous therapeutic pulmonary pulsation. Thus, this approach 
promises to be cost-effective. 
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By providing immediate improvement of myocardial microcirculation, the device could 
become a first priority in IHD as well as PAH managements. 
In future investigations, the device could be inserted through the PA (ongoing study ) or 
coronary sinus, either associated or not with an absorbable stent, to test for enhancements in 
the restoration of endothelial function. 
Over the long term, shear stress-induced endothelial regulation, alone or in combination 
with progenitors and angiogenic factors could promote cardio-circulatory rehabilitation and 
accelerate cardiogenesis. This approach might eliminate the need for interventional or 
surgical procedures. 
Finally, as far as the concept has been proven therapeutic efficiencies, there were some study 
limits that should be resolved in the future. This includes the severe vasodilatation as a 
result of direct intravascular endothelial stimulations by the intrapulmonary pulsatile 
catheter as well as the pulsatile tube as a LVAD. 
Interestingly, the application of the pulsatile tube alone as a LVAD without perfusion pump 
induced severe vasodilatation after impressive improvement of MI (please refer to operative 
movie). This is proving the hypersensitivity of the pulmonary endothelium as well as the LV 
endocardium that were responded rapidly to the unsynchronized tube pulsations. 
A similar phenomenon has been observed with Nicorandil, an exogenous NO donor used 
for angina pectoris relief (Falase BA, et al., 1999), (Blanc P, et al., 2001). 
Meanwhile, vasodilatation that could be induced by exogenous NO donors, leads to 
hypovolemic-cardiogenic shock. In contrast, the observed study hypovolemia, was preceded 
by general improvement of hemodynamic and organ microcirculation. This was manifested 
by the increased renal output manifested by a vesical globe that was released spontaneously 
in the pulsatile group animal models, which could be easily compensated by IV fluids. 
Currently we reduced the frequencies of pulsatile time (5-10 min), interrupted by interval 
pause guided by hemodynamic monitors, particularly systemic BP. 
There was no observed severe vasodilatation with the externally stimulated endothelial 
devices (the pulsatile trouser and mask). By caution, as the mechanism of vasodilatation is 
still undiscovered, also the improved microcirculation became almost steady after 15-20 min 
of external endothelial stimulations, our recommendation for the pulsatile suit sessions is: 
20-30 min. Furthermore, it is unnecessary to apply high-pressure pulsatile volume. A low 
pressure (1.2-2 bars) is sufficient to stimulate the superficial intravascular blood volume, 
covered by their endothelial stocks. 
Contraindications of the pulsatile suit, are more or less relatives as a non-invasive device, 
meanwhile cautions may be considered with some patients (e.g. hepatic cirrhosis, 
malignancy, open fractures, 3rd degree burns, colostomy, cerebral accidents, malignancy). 
Under all circumstances, Clinicians will determine contraindications according to the 
obtained results. 
Currently, clinical programs of the non-invasive devices will start very soon, with (Type A, 
& C) endothelial dysfunction  patients (e.g. CHF, resistant arterial hypertension, cerebral 
atherosclerosis, etc.) and others with healthy persons (Type C) e.g. bedridden, athletes. 
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12. Conclusion 
A promising therapeutic approach for CVD and circulatory disorders management with 
more physiological cost effective manners compared to current therapies. According to 
physics, it consists of: a shear rate intravascular enhancement device (catheter); a steady 
flow transformer device (tube) and an accessory circulatory driving forces enhancement 
and/or replacement device (suit). Drawbacks of the invasive devices could be overruled 
through accurate mathematical calculations of the induced momentum according to 
individual body surface area and the stimulated sites (blood column). Means, optimum 
devices performances could be achieved with computational models and biomedical 
engineering, to define the accurate device geometries as well as materials. 
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